€ million |
|
Note |
|
Dec. 31, 2020 |
|
Dec. 31, 2019 |
|
Jan. 1, 2019 |
||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Non-current assets |
|
|
|
|
|
|
|
|
||||
Goodwill |
|
|
15,959 |
|
17,114 |
|
13,764 |
|||||
Other intangible assets |
|
|
7,653 |
|
9,221 |
|
7,237 |
|||||
Property, plant and equipment |
|
|
6,421 |
|
6,192 |
|
4,811 |
|||||
Investments accounted for using the equity method |
|
|
|
2 |
|
– |
|
– |
||||
Other non-current financial assets |
|
|
822 |
|
738 |
|
656 |
|||||
Other non-current receivables |
|
|
25 |
|
22 |
|
17 |
|||||
Other non-current non-financial assets |
|
|
91 |
|
97 |
|
76 |
|||||
Deferred tax assets |
|
|
1,543 |
|
1,421 |
|
1,091 |
|||||
|
|
|
|
32,516 |
|
34,805 |
|
27,652 |
||||
Current assets |
|
|
|
|
|
|
|
|
||||
Inventories |
|
|
3,294 |
|
3,342 |
|
2,764 |
|||||
Trade and other current receivables |
|
|
3,221 |
|
3,488 |
|
3,226 |
|||||
Contract assets |
|
|
169 |
|
156 |
|
52 |
|||||
Other current financial assets |
|
|
125 |
|
57 |
|
29 |
|||||
Other current non-financial assets |
|
|
597 |
|
591 |
|
536 |
|||||
Income tax receivables |
|
|
520 |
|
589 |
|
460 |
|||||
Cash and cash equivalents |
|
|
1,355 |
|
781 |
|
2,170 |
|||||
|
|
|
|
9,280 |
|
9,003 |
|
9,236 |
||||
Total assets |
|
|
|
41,796 |
|
43,808 |
|
36,888 |
||||
|
|
|
|
|
|
|
|
|
||||
Total equity |
|
|
|
|
|
|
|
|||||
Equity capital |
|
|
|
565 |
|
565 |
|
565 |
||||
Capital reserves |
|
|
|
3,814 |
|
3,814 |
|
3,814 |
||||
Retained earnings |
|
|
|
12,378 |
|
11,483 |
|
11,192 |
||||
Gains/losses recognized in equity |
|
|
|
189 |
|
1,980 |
|
1,629 |
||||
Equity attributable to shareholders of Merck KGaA, Darmstadt, Germany |
|
|
|
16,946 |
|
17,841 |
|
17,200 |
||||
Non-controlling interests |
|
|
|
71 |
|
73 |
|
33 |
||||
|
|
|
|
17,017 |
|
17,914 |
|
17,233 |
||||
Non-current liabilities |
|
|
|
|
|
|
|
|
||||
Non-current provisions for employee benefits |
|
|
3,880 |
|
3,194 |
|
2,540 |
|||||
Other non-current provisions |
|
|
281 |
|
254 |
|
577 |
|||||
Non-current financial debt |
|
|
9,785 |
|
8,644 |
|
6,681 |
|||||
Other non-current financial liabilities |
|
|
62 |
|
43 |
|
33 |
|||||
Other non-current non-financial liabilities |
|
|
100 |
|
93 |
|
19 |
|||||
Deferred tax liabilities |
|
|
1,441 |
|
1,825 |
|
1,288 |
|||||
|
|
|
|
15,548 |
|
14,053 |
|
11,138 |
||||
Current liabilities |
|
|
|
|
|
|
|
|
||||
Current provisions for employee benefits |
|
|
152 |
|
110 |
|
112 |
|||||
Other current provisions |
|
|
461 |
|
823 |
|
488 |
|||||
Current financial debt |
|
|
2,357 |
|
4,550 |
|
2,215 |
|||||
Other current financial liabilities |
|
|
1,008 |
|
1,127 |
|
1,077 |
|||||
Trade and other current payables |
|
|
1,768 |
|
2,054 |
|
1,766 |
|||||
Refund liabilities |
|
|
666 |
|
565 |
|
472 |
|||||
Income tax liabilities |
|
|
1,460 |
|
1,402 |
|
1,176 |
|||||
Other current non-financial liabilities |
|
|
1,360 |
|
1,211 |
|
1,211 |
|||||
|
|
|
|
9,231 |
|
11,842 |
|
8,517 |
||||
Total equity and liabilities |
|
|
|
41,796 |
|
43,808 |
|
36,888 |
||||
|
||||||||||||
TAG overview
Results
- Please select a #tag from the overview (see above).
- To Our Shareholders
- Letter from Stefan Oschmann
- The Executive Board
- Our Shares
- In figures
- Management Report
- Fundamental Information about the Group
- The Group
- Our contributions to combating Covid-19
- Healthcare
- Life Science
- Performance Materials
- Strategy*
- Strategy Fundamentals
- Group Strategy
- Business Strategies
- Sustainability Strategy
- Strategic finance and dividend policy
- Internal Management System
- Key performance indicators
- Investments and value management
- Capital market-related parameters
- Other relevant/non-financial performance measures
- Sustainability*
- Innovations and technology
- Contribution of our technologies
- Sustainability culture and values
- Supply chain
- Social license
- Climate change and emissions
- Water and resource intensity
- Research and Development
- Healthcare*
- Life Science*
- Performance Materials*
- People*
- Leadership
- Talent
- Diversity and dialogue
- Differentiated solutions
- Report on Economic Position
- Macroeconomic Environment
- Review Forecast against Business Developments
- Course of Business and Economic Position
- Group
- Healthcare
- Life Science
- Performance Materials
- Corporate and Other
- Report on Risks and Opportunities
- Business-related risks and opportunities
- Financial risks and opportunities
- Legal risks
- Human resources risks
- Information technology risks
- Environmental, climate related and safety risks
- Risks due to the divestment, acquisition, and integration of companies and businesses
- Management assessment
- Report on Expected Developments
- Report in accordance with section 315 (4) of the German Commercial Code (HGB)
- Additional Information in accordance with the German Commercial Code (HGB)
- Corporate Governance
- Capital Structure and Corporate Bodies
- Statement on Corporate Governance
- Compensation Report
- Corporate governance practices
- Procedures of the Executive Board, Supervisory Board, Board of Partners, and its Committees
- Promote women in management positions
- Diversity policy
- Report of the Supervisory Board
- Objectives of the Supervisory Board
- Consolidated Financial Statements
- Income Statement
- Statement of Comprehensive Income
- Balance Sheet
- Cash Flow Statement
- Statement of Changes in Net Equity
- Notes
- General Disclosures
- (1) Company information
- (2) Reporting principles
- (3) Discretionary decisions and sources of estimation uncertainty
- (4) Subsequent events
- Group Structure
- (5) Changes in the scope of consolidation
- (6) Acquisitions and divestments
- (7) Collaboration and licensing agreements
- Operating Activities
- (8) Segment Reporting
- (9) Net sales
- (10) Cost of sales
- (11) Marketing and selling expenses
- (12) Research and development costs
- (13) Other operating income
- (14) Other operating expenses
- (15) Income tax
- (16) Net cash flows from operating activities
- (17) Earnings per share
- Operating Assets, Liabilities and Contingent Liabilities
- (18) Goodwill
- (19) Other intangible assets
- (20) Property, plant and equipment
- (21) Leasing
- (22) Other non-financial assets
- (23) Net cash flows from investing activities
- (24) Inventories
- (25) Trade and other receivables
- (26) Contract assets
- (27) Other provisions
- (28) Contingent liabilities
- (29) Other non-financial liabilities
- (30) Trade and other payables
- Employees
- (31) Number of employees
- (32) Personnel expenses
- (33) Provisions for employee benefits
- Capital Structure, Investments and Financing Activities
- (34) Equity
- (35) Cash and cash equivalents
- (36) Other financial assets
- (37) Financial debt/capital management
- (38) Other financial liabilities
- (39) Derivative financial instruments
- (40) Finance income and expenses/Net gains and losses from financial instruments
- (41) Net cash flows from financing activities
- (42) Management of financial risks
- (43) Information on fair value measurement
- (44) Other financial obligations
- Other Disclosures
- (45) Related party disclosures
- (46) Executive Board and Supervisory Board compensation
- (47) Auditor's fees
- (48) Corporate governance
- (49) Information on preparation and approval
- Scope of Consolidation
- (50) List of shareholdings
- Other Information
- Responsibility Statement
- Reproduction of the Independent Auditor's Report
- Business Development 2016 – 2020
- Financial Calendar